Records containing: Triple Negative Breast Cancer

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-04-02
An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in Early-stage Triple-negative Breast Cancer（NeoSACT）
CLINICAL_TRIALS study record update · 2026-04-01
Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer After Neoadjuvant Therapy
CLINICAL_TRIALS study record update · 2026-04-01
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
CLINICAL_TRIALS study record update · 2026-03-31
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
CLINICAL_TRIALS study record update · 2026-03-27
Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2026-03-27
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
CLINICAL_TRIALS study record update · 2026-03-27
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2026-03-27
Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC
CLINICAL_TRIALS study record update · 2026-03-20
PERCEPTION Trial Protocol: Comparison of Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumour-infiltrating Lymphocytes in Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2026-03-19
Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First/Second Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study
CLINICAL_TRIALS study record update · 2026-03-19
Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment
CLINICAL_TRIALS study record update · 2026-03-17
An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BFv; 9MW2821) in Subjects With Recurrent or Metastatic Triple-Negative Breast Cancer Previously Treated With Antibody-Drug Conjugates
CLINICAL_TRIALS study record update · 2026-03-17
A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2026-03-17
Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer (TNBC) Using Liquid Biopsy and Imaging: A Multi-Center Pilot Randomized Trial (EINSTEIN-TNBC)
CLINICAL_TRIALS study record update · 2026-03-16
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer With BRCA1, BRCA2, PALB2, RAD51C or RAD51D Mutations or RAD51-foci Low Test: RADIOLA TRIAL
CLINICAL_TRIALS study record update · 2026-03-16
The Cardiac Outcomes With Near-Complete Estrogen Deprivation (CROWN) Study
CLINICAL_TRIALS study record update · 2026-03-12
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
CLINICAL_TRIALS study record update · 2026-03-12
Feasibility of Serial Multisite Image-Guided Biopsy To Study Breast Cancer Evolution
CLINICAL_TRIALS study record update · 2026-03-04
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2026-03-04
Prospective Evaluation of the Breast Microbiome and Tumor Microenvironment-related Biomarkers of Response to Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2026-02-27
PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer
CLINICAL_TRIALS study record update · 2026-02-27
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
CLINICAL_TRIALS study record update · 2026-02-25
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2026-02-25
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer
CLINICAL_TRIALS study record update · 2026-02-24
A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer